TORONTO, July 12, 2018 /CNW/ - GeneNews Limited ("GeneNews" or the "Company") (TSX:GEN) today announced the appointment of David Byram as the Chief Commercial Officer for its U.S. Lab, Innovative Diagnostic Laboratory, LLP ("IDL"). Mr. Byram will oversee all IDL's customer-facing activities including sales, client relations and commercial operations.
Mr. Byram is a senior commercial executive with over 25 years of pharmaceutical, biotechnology and medical device industry leadership experience. He has built successful product launches across multiple therapeutic areas that incorporate innovative sales and marketing strategies which have driven wide market adoption and revenue generation. Mr. Byram has broad health category experience including oncology/hematology, gastroenterology, rheumatology, neurology, cardiology and urology. During his career, Mr. Byram has overseen all commercial operations including sales and marketing, market access and pricing, channel strategy and new product development. Prior to joining IDL, Mr. Byram was the Vice President, Commercial & Government Affairs for Braeburn Pharmaceuticals. Prior to Braeburn, he held positions as SVP, Commercial Affairs for Orexo AB/US, US Director, Public Sector for Indivior plc, and Sr. Director, Strategic Accounts and Public Affairs for Janssen Biotech, a division of Johnson & Johnson. David is highly focused on delivering healthcare outcomes which create value for patients, physicians, payers and investors.
"We are extremely pleased to have David join IDL's senior leadership team," commented James R Howard-Tripp, Chairman and CEO of GeneNews. "With a very experienced executive to energetically manage the company's commercial operations and sales strategy, we can increase the pace of meeting our targeted sales objectives for 2018."
"It is an exciting time to be in the liquid biopsy space and I look forward to utilizing my commercialization expertise as well as prior sales experience in oncology and gastroenterology to support IDL's efforts to achieve our growth objectives and ensure the highest satisfaction of our clients," said Mr. Byram.
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease.
Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
This press release contains forward-looking statements identified by words such as "expects", "will", "may" and similar expressions, which reflect the Company's current expectations regarding future events, including with respect to the receipt of shareholder approval. The forward-looking statements involve risks and uncertainties that could cause actual events to differ materially from those projected herein including the state of the equity capital markets, the receipt of required approvals, the future financial and operating performance of the Company and its subsidiaries, requirements for and availability of additional capital and the general business and political environment including in the healthcare sector. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
SOURCE GeneNews Limited
For further information: Company Contact James R. Howard-Tripp, Chairman & CEO, [email protected]